To review the current scenario of MASLD/MASH diagnosis and management in Japan, focusing on epidemiology, diagnosis, treatment strategies, and the significance of patient-centric approaches.
Key Findings:
The prevalence of MASLD in Japan was reported at 25.9% in individuals over 50 years in 2019, with a projected rise to 44.8% by 2040 due to increasing metabolic risk factors.
Lean MASLD accounted for 20.7% of the MASLD population in Japan, highlighting the need for awareness of this subgroup.
Emerging therapies and non-invasive assessment methods are reshaping the management of MASLD/MASH, necessitating updated clinical guidelines.
There is a significant increase in MASLD prevalence in Japan, projected to rise to 44.8% by 2040, emphasizing the urgency for effective management strategies.
Interpretation:
The shift from viral to non-viral causes of liver disease in Japan necessitates a personalized treatment approach for MASLD/MASH, given the rising prevalence and associated health risks, which may influence healthcare policy.
Limitations:
Lack of standardized guidelines for MASLD/MASH management, which complicates treatment strategies.
Biological variability and differences in clinical practices complicate treatment strategies, potentially affecting patient outcomes.
Conclusion:
A comprehensive understanding of MASLD/MASH is crucial for effective management in Japan, highlighting the need for awareness, tailored therapeutic approaches, and addressing the identified limitations.
Mayo Clinic Children's delivers comprehensive care for children with liver disease, from early evaluation and second opinions to advanced therapies and pediatric liver transplantation.
